-+ 0.00%
-+ 0.00%
-+ 0.00%

EIKON THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TELURIDE-008, A REGISTRATIONAL PHASE 2/3 TRIAL OF EIK1001 IN NON-SMALL CELL LUNG CANCER

Reuters·07/27/2026 11:30:00

Please log in to view news